FIN56
|
| Katalog-Nr.GC30039 |
FIN56, ein neuartiger Ferroptose-Induktor, löst Ferroptose aus, indem es den Abbau von GPX4 erhöht.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1083162-61-1
Sample solution is provided at 25 µL, 10mM.
FIN56, ein neuartiger Ferroptose-Induktor, löst Ferroptose aus, indem es den Abbau von GPX4 erhöht [1,4]. FIN56 aktiviert auch die Squalen-Synthase, ein Enzym, das an der Cholesterinsynthese beteiligt ist [2].
FIN56 (0-8,0 µM; 24 h) verringerte die Zellviabilität von LN229- und U118-Zellen dosisabhängig. Nach der Behandlung mit FIN56 wurde der Zellzyklus von LN229 und U118 in den GO/G1-Phasen arretiert [3]. FIN56 (1-5 µM; 3-24 h) induziert autophagie-assoziierten Zelltod in Blasenkrebszellen (BC) [4]. Die Hemmung von GPX4 durch FIN56 (0-20 µM) hob die schützenden Effekte von NAC auf die HG-induzierte Ferroptose auf [5]. Die Proteinausdruck von Salusin-β wurde durch Ferroptose-Aktivatoren wie FIN56 hochreguliert. Eine Vorbehandlung mit Ferrostatin-1 (einem Ferroptose-Inhibitor) verhinderte die Hochregulierung der Proteinexpression von Salusin-β in HK-2-Zellen, die HG ausgesetzt waren [6]. AS-IV beschleunigte die Proliferation deutlich, unterdrückte die Apoptose und verringerte die Ansammlung von ROS und LDH. Die Effekte von AS-IV auf SCI wurden durch si-TFEB gehemmt, und diese Hemmung wurde durch die Zugabe von FIN56 (5 µM) weiter verstärkt [7].
FIN56 (30 Tage) verringerte das Tumorvolumen deutlich und erhöhte signifikant die Proteinniveaus von 4-HNE [3].
References:
[1]. Shimada K, Skouta R, et,al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat Chem Biol. 2016 Jul;12(7):497-503. doi: 10.1038/nchembio.2079. Epub 2016 May 9. PMID: 27159577; PMCID: PMC4920070.
[2]. Gaschler MM, Andia AA, et,al.FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat Chem Biol. 2018 May;14(5):507-515. doi: 10.1038/s41589-018-0031-6. Epub 2018 Apr 2. PMID: 29610484; PMCID: PMC5899674.
[3]. Zhang X, Guo Y, et,al. FIN56, a novel ferroptosis inducer, triggers lysosomal membrane permeabilization in a TFEB-dependent manner in glioblastoma. J Cancer. 2021 Sep 13;12(22):6610-6619. doi: 10.7150/jca.58500. PMID: 34659551; PMCID: PMC8517990.
[4]. Lei P, Bai T, et,al.Mechanisms of Ferroptosis and Relations With Regulated Cell Death: A Review. Front Physiol. 2019 Feb 26;10:139. doi: 10.3389/fphys.2019.00139. PMID: 30863316; PMCID: PMC6399426.
[5]. Li Q, Liao J,et,al. NAC alleviative ferroptosis in diabetic nephropathy via maintaining mitochondrial redox homeostasis through activating SIRT3-SOD2/Gpx4 pathway. Free Radic Biol Med. 2022 Jul;187:158-170. doi: 10.1016/j.freeradbiomed.2022.05.024. Epub 2022 May 31. Erratum in: Free Radic Biol Med. 2022 Aug 20;189:1. PMID: 35660452.
[6].Wang WJ, Jiang X,et,al.Salusin‑β participates in high glucose‑induced HK‑2 cell ferroptosis in a Nrf‑2‑dependent manner. Mol Med Rep. 2021 Sep;24(3):674. doi: 10.3892/mmr.2021.12313. Epub 2021 Jul 23. PMID: 34296310; PMCID: PMC8335735.
[7]. Zhou Y, Li L, et,al.Astragaloside IV ameliorates spinal cord injury through controlling ferroptosis in H2O2-damaged PC12 cells in vitro. Ann Transl Med. 2022 Nov;10(21):1176. doi: 10.21037/atm-22-5196. PMID: 36467371; PMCID: PMC9708485.
| Cell experiment [1]: | |
Cell lines | LN229 and U118 GBM cell lines |
Preparation Method | Cells were plated into 96-well plates and incubated overnight. Different doses of FIN56 (0, 0.1, 0.5, 1.0, 2.0 4.0 and 8.0 µM) was added to wells. 24 h later, CCK-8 solution was added to each well. 2 h later, samples were measured at 450 nm on a microplate reader. |
Reaction Conditions | FIN56 (0-8.0 µM);24 h |
Applications | FIN56 decreased the cell viability of LN229 and U118 cells in a dose-dependent manner. |
| Animal experiment [1]: | |
Animal models | Nude mouse model |
Preparation Method | LN229 cells were injected subcutaneously into the right shoulder of 4-week-old nude mice. 2 weeks later, nude mice (n = 10) were divided into two groups, control group and FIN56 treatment group. Subcutaneous tumors were harvested 30 days after treatment. |
Dosage form | 30 days |
Applications | FIN56 decreased tumor volume obviously, FIN56 significantly increased protein levels of 4-HNE. |
References: | |
| Cas No. | 1083162-61-1 | SDF | |
| Canonical SMILES | O=S(C1=CC(/C2=N\O)=C(C3=C2C=C(S(=O)(NC4CCCCC4)=O)C=C3)C=C1)(NC5CCCCC5)=O | ||
| Formula | C25H31N3O5S2 | M.Wt | 517.66 |
| Löslichkeit | DMSO : ≥ 100 mg/mL (193.18 mM);Water : < 0.1 mg/mL (insoluble) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9318 mL | 9.6588 mL | 19.3177 mL |
| 5 mM | 0.3864 mL | 1.9318 mL | 3.8635 mL |
| 10 mM | 0.1932 mL | 0.9659 mL | 1.9318 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *